Midgard Science

Labs / ADME, DMPK & toxicology

Ablevia biotech

Vienna, Austria · ablevia.com

Ablevia biotech develops a selective antibody removal pre-treatment platform for advanced biologics and delivery systems. It works with partners developing therapies affected by anti-drug or anti-vector antibodies, including PEGylated drugs and PEGylated LNP-based RNA and DNA delivery, from Vienna, Austria.

They take quote requests by email.

What they offer

  • Selective antibody removal pre-treatment platform

    An injectable pre-treatment platform based on Selective Antibody Depletion Compounds (SADCs) that removes circulating anti-drug and anti-vector antibodies before dosing.

  • Anti-PEG antibody depletion

    A lead SADC program that rapidly removes anti-PEG antibodies to restore the performance of PEGylated drugs and PEGylated LNP delivery.

  • Selective antibody depletion for advanced therapeutics

    Development of next-generation SADCs intended to target protein-directed anti-drug and anti-vector antibodies for broader therapeutic use.

  • ADA epitope profiling support

    Deep profiling of ADA epitopes to guide the design and expansion of selective antibody removal programs.

What they work on

Modalities
Antibody, LNP / formulation
Assays and studies
ADA epitope profiling
Therapeutic areas
oncology, rare diseases, metabolic diseases
Sites
Vienna, Austria

Similar labs. Transcenta Holding, Aurigene Pharmaceutical Services, Bioklone Biotech Private Limited, Bioneeds

Found in a contract services directory. Listing built from ablevia.com. Work here? Claim this listing.

Ablevia biotech · Midgard Science